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Abstract In individuals with multiple sclerosis, physical
and cognitive disability progression are clinical and
pathophysiological hallmarks of the disease. Despite
shortcomings, particularly in capturing cognitive deficits,
the Expanded Disability Status Scale is the assessment of
disability progression most widely used in clinical trials.
Here, we review treatment effects on disability that have
been reported in large clinical trials of disease-modifying
treatment, both among patients with relapsing–remitting
disease and among those with progressive disease. How-
ever, direct comparisons are confounded to some degree by
the lack of consistency in assessment of disability pro-
gression across trials. Confirmed disability progression
(CDP) is a more robust measure when performed over a
6-month than a 3-month interval, and reduction in the risk
of 6-month CDP in phase III trials provides good evidence
for the beneficial effects on disability of several high-effi-
cacy treatments for relapsing–remitting disease. It is also
becoming increasingly clear that therapies effective in re-
lapsing–remitting disease have little impact on the course
of progressive disease. Given that the pathophysiological
mechanisms, which lead to the long-term accrual of phy-
sical and cognitive deficits, are evident at the earliest stages
of disease, it remains a matter of debate whether the most
effective therapies are administered early enough to afford
patients the best long-term outcomes.
Key Points
Several high-efficacy immune therapies can reduce
the risk of disability progression in relapsing–
remitting multiple sclerosis.
A standard definition of disability progression would
facilitate comparative evaluation of therapies.
In relapsing multiple sclerosis, and potentially in
certain progressive phenotypes, the best outcomes
may be afforded by early treatment with the most
effective immune therapies.
1 Introduction
Disability progression is a key clinical outcome in patients
with multiple sclerosis (MS) that was originally assessed
using the Disability Status Scale (DSS) [1]. The DSS was
superseded by an expanded version of the scale [Expanded
DSS (EDSS)], with which worsening disability can be
scored in 0.5-point increments from 0 (normal neurological
status) to 10 (death due to MS) [2]. Without treatment,
patients with MS accrue moderate levels of disability (DSS
score of 3) on average within 8 years of diagnosis, and
need assistance walking (DSS score of 6) within 15 years
of diagnosis [3]. Compounded by the unpredictable and
debilitating nature of relapses experienced by many pa-
tients early in the disease course, even moderate levels of
disability can be highly disruptive to normal living. A
retrospective analysis of the Danish MS patient registry
found that the median time from onset of MS to retirement
(receipt of an early pension) was 10 years, compared with
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24 years among matched control individuals [4]. A study
of patients in nine European countries found an unem-
ployment rate of 50 % among patients of working age with
an EDSS score of 3.0, and also found a steady decline in
utility score [calculated from the 5-dimension European
Quality of Life (EuroQol) questionnaire] with increasing
EDSS score [5].
The EDSS focuses mainly on motor function and am-
bulation, but captures cognitive decline poorly and has
several other shortcomings [6]: ambiguity in the original
rules for scoring affects reproducibility among raters,
especially in the range 0–4.0 [7–10]; the scale is non-linear
(i.e. the clinical importance of a 1-point increase varies
depending on initial score) and a patient’s rate of pro-
gression through the scale also depends on baseline score
[11]. This situation prompted development of the MS
Functional Composite (MSFC), which assesses disability
progression based on dexterity (Nine-Hole Peg Test), am-
bulation (Timed 25-Foot Walk Test) and cognitive function
[Paced Auditory Serial Addition Test (PASAT)] [12, 13].
The MSFC has advantages over the EDSS, and is included
as an endpoint in many studies, but it also has limitations:
z scores (the summary score from the three components)
are difficult to interpret; learning effects can skew PASAT
on repeated use; and assessment of visual impairment is
excluded [14].
Here, we review evidence for the potential of disease-
modifying treatments (DMTs) to delay disability progression
in patients with MS. We summarize disability data from all
completed phase III trials of both approved and experimental
therapies inpatientswith all forms ofMS, grouping treatments
by route of administration. Disability data from phase II trials
are also reported, and a number of failed or inconclusive trials
are listed, although these have been reviewed extensively
elsewhere [15, 16]. The EDSS is the assessment most com-
monly used in MS trials (relatively few report changes in
MSFC score), therefore we focus on measures related to
EDSS score, such as confirmed disability progression (CDP),
which is usually based onchanges in the score sustainedover 3
or 6 months; of these, 6-month CDP is the more robust indi-
cator of permanent disability progression [17, 18]. Generally,
CDP is defined as a 1.0-point increase if the EDSS score is less
than 5.5 at baseline (sometimes a 1.5-point increase if EDSS
score is 0), and as a 0.5-point increase if the baseline EDSS
score is at least 5.5, but variations in these criteria are noted.
Reflecting the current treatment landscape, the majority
of trials are in patients with relapsing–remitting MS
(RRMS), rather than clinically isolated syndrome (CIS),
primary progressive MS (PPMS) or secondary progressive
MS (SPMS), and although used in the trials discussed here,
some of this nomenclature has been recently superseded
[19]. Trials are therefore grouped as pertaining to relaps-
ing–remitting or to progressive disease.
2 Therapies in Patients with Relapsing–Remitting
MS
Summary trial information and baseline characteristics are
shown in Table 1 and disability outcomes from each trial
are provided in Table 2.
2.1 Approved Oral Therapies
2.1.1 Fingolimod
Fingolimod (Gilenya,Novartis)was thefirst oral therapyused
in the treatment of patients with RRMS, and has shown evi-
dence of reducing disability progression in phase III trials [20–
22]. It is approved in the USA for treating patients with re-
lapsing forms of MS [23], and in the EU either as first-line
therapy in patients with rapidly evolving severe RRMS or as
second-line treatment in patients with RRMS and high disease
activity despite treatment with at least one DMT [24]. Com-
pared with placebo, fingolimod 0.5 mg (approved daily dose)
reduced the respective risk of 3-month and 6-monthCDPby 30
and 37 %, respectively, in FREEDOMS (p\0.05, both) [20],
but had anon-significant effect onCDP inFREEDOMSII [21].
Thefinding inFREEDOMSIIwas attributed to highvariability
in disability progression among patients with baseline EDSS
scores of 0, and an exploratory analysis that excluded these
patients found a significant reduction in the risk of 3-month
CDP with fingolimod 0.5 mg versus placebo [hazard ratio
(HR), 0.70; 95 % confidence interval (CI): 0.50, 0.98;
p = 0.040]. Proportionately more patients had 3-month CDP
in FREEDOMS II than in FREEDOMS, and the proportions
with 6-month CDP were similar in both studies. A relatively
small proportion of patients had 3-month CDP in the 1-year
TRANSFORMS trial, and neither the 29 % reduction in risk of
3-month CDP with fingolimod 0.5 mg versus intramuscular
interferon (IFN) beta-1a, nor the between-group difference in
EDSS score reached significance [22, 24]. However, changes
in MSFC scores were beneficial on fingolimod 0.5 mg com-
pared with controls in all three trials [20–22].
2.1.2 Teriflunomide
Teriflunomide (Aubagio, Genzyme) was the second oral
drug approved in both the EU and the USA for use in adults
with RRMS [25, 26]. Two pivotal placebo-controlled, phase
III trials of teriflunomide have been conducted in patients
with RRMS (TEMSO [27] and TOWER [28]) and another
trial in CIS (TOPIC [29]). In the 2-year TEMSO trial, pa-
tients receiving teriflunomide 14 mg had a 30 % reduction in
risk of 3-month CDP compared with those receiving placebo
(p\ 0.05) [27], and at the 14-mg dose in TOWER there was
a 32 % risk reduction in time to sustained disability



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Disease-Modifying Treatment of Disability Progression in MS 959
progression (a key secondary endpoint based on 3-month
CDP; p\ 0.05). Reductions in the risk of 6-month CDP
failed to reach significance in either study [25] and no sig-
nificant changes in MSFC were reported in TEMSO [30]. At
12 months in TOWER there was a small decrease from
baseline EDSS score in the 14-mg group (p\ 0.05) com-
pared with the placebo group [28], and in TOPIC there was a
significantly greater reduction in EDSS scores at 24 months
with teriflunomide 14 mg comparedwith placebo (p\ 0.05)
[29]. Reductions in 3-month CDP, however, were not sig-
nificant in the TOPIC study [29], which used the same CDP
criteria as TEMSO. A fourth phase III trial, TENERE, which
compared teriflunomide with subcutaneous IFN beta-1a,
assessed a composite endpoint of time to disease relapse or
treatment discontinuation, rather than evaluating disability
as a separate endpoint [31]. Accrual of at least a 0.5-point
increase in EDSS score, however, was one possible criterion
for disease relapse. No differences were reported for the
composite endpoint comparing teriflunomide with subcuta-
neous IFN beta-1a.
2.1.3 Dimethyl Fumarate
Dimethyl fumarate (DMF; BG-12; BG00012; Tecfidera,
Biogen Idec) is approved in the EU and USA for the
treatment of adult patients with RRMS [32, 33]. Two
2-year, placebo-controlled phase III trials (CONFIRM [34]
and DEFINE [35]) have been reported; CONFIRM also
included a reference group randomized to subcutaneous
glatiramer acetate (GA). In CONFIRM, reduction in risk of
3-month CDP was not significant compared with placebo,
regardless of whether DMF was administered twice or
three times a day [34]. In the DEFINE trial, a 38 % re-
duction in risk of 3-month CDP was noted for the approved
regimen of 240 mg twice a day (p\ 0.01) [35]; neither
trial reported a reduction in the risk of 6-month CDP [32,
36]. Both trials used slightly more stringent criteria for
CDP than were generally used elsewhere (a 1.0-point in-
crease, or a 1.5-point increase if EDSS score is 0 at base-
line) [34, 35]. Improvements in MSFC score were observed
in both trials but were not statistically significant [36].
2.2 Oral Therapies Not Currently Approved
2.2.1 Laquinimod
Laquinimod (Nerventra, Teva), an oral im-
munomodulator as yet unapproved for use in patients with
MS, has been compared with placebo for the treatment of
RRMS in the 2-year, phase III placebo-controlled
ALLEGRO [37] and BRAVO [38] trials; BRAVO also
included a comparator group receiving intramuscular IFN
beta-1a. Significant reductions in the risk of 6-month CDP
among patients receiving laquinimod 0.6 mg/day com-
pared with placebo were reported in both ALLEGRO
(49 %; p\ 0.01) and BRAVO (39 %; p\ 0.05), and the
risk of 3-month CDP was also reduced in ALLEGRO
(36 %, p\ 0.05). In BRAVO there was a non-significant
31 % reduction in 3-month CDP; changes in MSFC scores
from baseline were non-significant versus placebo in both
studies [37, 38].
2.2.2 Cladribine
Cladribine (Movectro, Merck Serono), an oral therapy
approved for treatment of patients with hairy cell leukemia,
was evaluated in patients with MS in the phase III
CLARITY [39] and ORACLE MS [40] trials; however,
clinical development was suspended in 2011 pursuant to
safety concerns [41] and ORACLE MS terminated before
disability outcomes were assessed [40]. The 2-year
CLARITY trial used the same 3-month CDP criteria as did
the phase III trials of DMF (a 1.0-point increase in EDSS
score from baseline, or a 1.5-point increase if EDSS score
is 0). At both doses of cladribine tested, the risk of 3-month
CDP was approximately 50 % lower than with placebo
(p\ 0.05, both) [39].
2.2.3 Azathioprine
Azathioprine has been used to treat patients with MS for
over 30 years, but its use was largely superseded by the
advent of IFN beta-based therapies; however, a recent trial
demonstrated its non-inferiority to IFN beta in patients
with RRMS, including the finding that there was no sig-
nificant between-group difference in the proportion of pa-
tients with 6-month CDP [42].
2.3 Approved Intravenous Therapies
2.3.1 Alemtuzumab
Alemtuzumab [Lemtrada, Genzyme (Sanofi)] is an anti-
CD52 monoclonal antibody (mAb) originally indicated for
second-line therapy in patients with B-cell chronic lym-
phocytic leukemia, that was re-licensed in the EU (2013)
and in the USA (2014) for intravenous treatment of re-
lapsing forms of MS, with active disease defined by clinical
or imaging features [43, 44]. At the approved dose of
12 mg/day for 5 days, alemtuzumab was compared with
subcutaneous IFN beta-1a in the 2-year, phase III CARE-
MS I [45] and CARE-MS II [46] trials (some patients were
also randomized to alemtuzumab 24 mg/day in CARE-MS
II, but this was discontinued following a protocol amend-
ment designed to accelerate recruitment into the other
treatment groups). Disability was a co-primary endpoint in
960 H. Wiendl, S. G. Meuth
both trials, defined as 6-month CDP with a 1.0-point in-
crease in EDSS score from baseline, or a 1.5-point increase
if EDSS score was 0. Compared with subcutaneous IFN
beta-1a, a 42 % reduction in risk of CDP was seen among
patients receiving alemtuzumab in CARE-MS II (p\ 0.01)
[46], but the 30 % reduction seen in CARE-MS I was not
significant [45]. In CARE-MS II, the improvement in mean
EDSS score (p\ 0.001) was significant compared with
that observed with subcutaneous IFN beta-1a [46], but
there was no between-group difference in EDSS score in
CARE-MS I [45]. Patients eligible for CARE-MS I were
treatment-naı¨ve, unlike those eligible for CARE-MS II,
who had disease breakthrough on first-line IFN beta or GA.
Also in CARE-MS I, a lower proportion of patients in the
subcutaneous IFN beta-1a control group had 6-month CDP
(11 %) [45] than in CARE-MS II (21 %) [46]. Changes in
MSFC scores in both studies were significant when con-
sidered in isolation, but not when considered in the context
of a pre-specified hierarchical analysis of secondary
endpoints.
2.3.2 Natalizumab
Natalizumab (Tysabri, Biogen Idec) is a humanized anti-a4
integrin mAb approved in the USA for the treatment of re-
lapsing forms of MS and in the EU for the treatment of
rapidly evolving severe RRMS and highly active RRMS
among patientswith disease breakthrough on IFNbeta orGA
[47, 48]. Administered intravenously at the approved dose of
300 mg every 4 weeks, natalizumab has been tested in two
2-year, phase III trials: AFFIRM [49], which was placebo-
controlled; and SENTINEL [50], in which all patients con-
tinued intramuscular IFN beta-1a after randomization to
natalizumab or placebo. The rate of 3-monthCDP (defined as
a 1.0-point increase in EDSS score from baseline, or a 1.5-
point increase if EDSS score was 0) was the co-primary
endpoint in both studies. Risk reductions of 42 % (AFFIRM;
p\ 0.001) and of 24 % (SENTINEL; p\ 0.05) were
demonstrated; and a 54 % reduction in the risk of 6-month
CDP (p\ 0.001) was reported in AFFIRM [48–50].
2.3.3 Mitoxantrone
Mitoxantrone (Novantrone, EMD Serono) is an antineo-
plastic type II topoisomerase inhibitor used to treat patients
with worsening or aggressive RRMS. Not currently ap-
proved throughout the EU, it is a therapy option in Ger-
many and is approved for use in the USA [51]. Controlled
trials of mitoxantrone involving patients with RRMS or
worsening RRMS include: a 6-month study in which pa-
tients received methylprednisolone with or without mi-
toxantrone [52]; a 1-year placebo-controlled trial with a
1-year follow-up [53]; the 2-year placebo-controlled MIMS
trial [54] (please also see Sect. 3.1.1); and, more recently, a
3-year study by the French–Italian Mitoxantrone IFN beta-
1b Trial Group [55], which randomized patients either to
mitoxantrone and intravenous methylprednisolone monthly
for 6 months followed by subcutaneous IFN beta-1b for
27 months, or to subcutaneous IFN beta-1b for 3 years
combined with monthly methylprednisolone for the first
6 months. Compared with controls, mitoxantrone treatment
reduced the proportion of patients with at least a 1.0-point
increase in EDSS score from baseline in the 6-month study
(p\ 0.01), and reduced the risk of 3-month CDP (defined
as a 1.0-point increase in EDSS score) by 30 % (p\ 0.05)
at 2 years [53], and by 65 % at 3 years [55].
2.4 Approved Injectable Therapies
2.4.1 Glatiramer Acetate
Approved in the USA and EU in patients with CIS and
RRMS [56, 57], GA (Copaxone, Teva) has been
evaluated in six phase III trials [34, 58–62]. It was com-
pared with placebo in two trials (GALA in patients with
RRMS [58] and PreCISe in individuals with CIS [59]),
with subcutaneous IFN beta-1a in REGARD [60], was an
active comparator in two trials in patients with RRMS (the
placebo-controlled CONFIRM trial of DMF [34] and the
BEYOND trial of subcutaneous IFN beta-1b [61]), and was
evaluated in combination with intramuscular IFN beta-1a
in a placebo-controlled trial in patients with RRMS
(CombiRx [62]). No large trials have reported an effect of
GA on CDP relative to control treatment.
2.4.2 IFN beta
The three IFN beta-based therapies are the most long-
standing approved DMTs for patients with RRMS and CIS,
subcutaneous IFN beta-1b originally being licensed in the
USA in 1993 [63] then in the EU in 1995 [64]. Intramus-
cular IFN beta-1a (Avonex, Biogen Idec [65, 66]), sub-
cutaneous IFN beta-1a (Rebif, Merck Serono [67, 68])
and subcutaneous IFN beta-1b (Extavia, Novartis [69,
70]; Betaferon, Bayer [71, 72]) have been included in at
least 18 phase III trials, either as the focus of investigation
[61, 62, 73–82] or as reference compounds [22, 31, 38, 45,
46, 50, 55]. In the 2-year MSCRG study, proportionately
fewer patients with RRMS had 6-month CDP on intra-
muscular IFN beta-1a than on placebo, and time to
6-month CDP was greater than with placebo (p = 0.02)
[73]; disability endpoints were not reported in CHAMPS in
patients with CIS [74]. In the PRISMS trial, there was a
smaller increase in EDSS score over 2 years in both sub-
cutaneous IFN beta-1a dose groups than in the placebo
group [75], and subcutaneous IFN beta-1a was associated
Disease-Modifying Treatment of Disability Progression in MS 961
with non-significant reductions in the risk of 3-month and
6-month CDP compared with intramuscular IFN beta-1a in
EVIDENCE [76, 77]; disability endpoints were not re-
ported in IMPROVE [78] or among patients with CIS in
REFLEX [79]. In the ADVANCE study [83] of subcuta-
neous pegylated IFN beta-1a (Plegridy, Biogen Idec
[84]), there was a 38 % lower risk of 6-month CDP
(p\ 0.05) among patients treated every 2 weeks for
2 years compared with those who received placebo in
year 1 followed by treatment every 2 weeks in year 2 [85].
Finally, with subcutaneous IFN beta-1b there was a non-
significant reduction in 3-month CDP compared with
placebo in the IFNB study in patients with RRMS [80].
Generally, there were no between-group differences in
disability measures at the 8-year follow-up [86] of the
BENEFIT study [81], which examined the impact of de-
laying treatment initiation by 1 year in patients with CIS.
The exception was that throughout the study period, the
early-treatment group scored higher than the delayed-
treatment group on PASAT (p\ 0.05). There were no
between-group differences in the proportions of patients
with 3-month CDP in the BEYOND study of subcutaneous
IFN beta-1b and GA [61]. These findings are somewhat
contradicted by the 2-year INCOMIN study [82], in which
the risk of 6-month CDP was 56 % lower with subcuta-
neous IFN beta-1b than with intramuscular IFN beta-1a
(p\ 0.01).
2.5 Injectable Therapies Not Currently Approved
2.5.1 Daclizumab High-Yield Process
The randomized DECIDE trial compared subcutaneous
daclizumab high-yield process (DAC HYP; Biogen Idec
and Abbvie) with intramuscular IFN beta-1a administered
over 96–144 weeks, in patients with RRMS [87]. Provi-
sional results ahead of publication indicated no significant
between-group difference in 3-month CDP [88].
3 Therapies in Patients with Progressive Forms
of MS
Summary trial information and baseline characteristics are
shown in Table 3 and disability outcomes from each trial
are provided in Table 4.
3.1 Approved Intravenous Therapies
3.1.1 Mitoxantrone
Approved in Germany and the USA for the treatment of
patients with SPMS and progressive relapsing MS [51],
mitoxantrone 12 mg/m2 was associated with a small re-
duction in EDSS score from baseline in the 2-year placebo-
controlled MIMS trial. Although interpretation is somewhat
confounded by the fact that the trial was conducted in a
mixed population of patients with progressive relapsing MS
or SPMS, this reduction in EDSS score represented a sig-
nificant treatment benefit compared with placebo (p =
0.0194). Time to 3-month and to 6-month CDP (increase in
EDSS score of C1 point) was also greater in these patients
than in those receiving placebo (p = 0.03, both) [54].
3.2 Intravenous Therapies Not Currently Approved
3.2.1 Cladribine
Intravenous cladribine has been evaluated in two phase III
placebo-controlled trials in patients with progressive MS,
but neither study reported values for 3-month or 6-month
CDP [89, 90]. Evidence for an effect on disability pro-
gression was presented in the earlier, smaller trial (n = 48)
[89], but no effect (based on changes in EDSS score) was
seen in the subsequent larger trial of patients with PPMS
(n = 48) or SPMS (n = 111) [90].
3.2.2 Rituximab
The OLYMPUS trial of intravenous rituximab in patients
with PPMS found no effect of treatment on time to
3-month CDP. A significant delay in time to 3-month CDP
was identified in planned subgroup analyses of patients
with gadolinium-enhanced lesions on magnetic resonance
imaging (MRI) at baseline (HR 0.41; p = 0.007) and in
patients aged younger than 51 years (HR 0.52; p = 0.010),
and the effect was augmented in the subgroup with both
characteristics (HR 0.33; p = 0.009) [91].
3.2.3 Dirucotide (MBP8298)
The 2-year MAESTRO-01 trial examined the efficacy of
dirucotide (MBP8298; Eli Lilly) in patients with SPMS and
with human leukocyte antigen (HLA) haplotypes DR2? or
DR4? [92]. No effect of treatment on disability progression
was seen in MAESTRO-01, leading to the termination of
phase III trials MAESTRO-02 and MAESTRO-03.
3.2.4 Intravenous Immunoglobulin
A randomized, 2-year, placebo-controlled trial of intra-
venous immunoglobulin (IVIG) in a mixed population of
patients with PPMS (n = 34) or SPMS (n = 197) found
that time to sustained disability progression was 12 weeks
longer among patients receiving treatment than in those
taking placebo (p = 0.0406) [93].










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































966 H. Wiendl, S. G. Meuth
3.3 Approved Injectable Therapies
3.3.1 IFN Beta
Among the IFN beta-based therapies, only subcutaneous
IFN beta-1b has received approval in the EU for treatment
of progressive disease, specifically in relapsing forms of
SPMS [70, 72]. Placebo-controlled trials of subcutaneous
IFN beta-1b in Europe [94] and in North America [95]
among patients with SPMS yielded different findings.
There was a significant increase in time to 3-month CDP
with treatment in the European trial compared with placebo
(p = 0.0008) [94], but no effect on 6-month CDP was re-
ported in the North American trial [95]. However, a post
hoc meta-analysis of the two trial populations found an
overall reduction in the risk of 6-month CDP (HR, 0.79;
95 % CI: 0.66, 0.93; p = 0.0076) [96]. Unfortunately, no
such benefit was seen among patients with PPMS in a
subsequent 2-year placebo controlled trial of subcutaneous
IFN beta-1b [97]. Subcutaneous IFN beta-1a is a treatment
option in Germany for relapsing forms of SPMS, although
no effect on disability measures was reported in either of
two 3-year placebo-controlled trials in patients with SPMS
(SPECTRIMS [98]; the Nordic SPMS trial [99]); no phase
III trials of subcutaneous IFN beta-1a in patients with
PPMS have been reported.
3.4 Injectable Therapies Not Currently Approved
3.4.1 Intramuscular IFN Beta-1a
No improvement in time to 3-month CDP with intramus-
cular IFN beta-1a was seen among patients with PPMS
[100], or among patients with SPMS in the 2-year
IMPACT trial [101]. However, a significant improvement
in MSFC scores (the primary endpoint) was seen at 2 years
with intramuscular IFN beta-1a compared with placebo
(p = 0.033).
3.4.2 Glatiramer Acetate
The placebo-controlled PROMiSe trial of GA in patients
with PPMS was terminated when an interim analysis re-
vealed no treatment effect on time to 3-month CDP, the
primary outcome [102].
4 Discussion
The goal of DMT in patients with MS is to prevent the
accrual of physical and cognitive deficits associated with
disease worsening. Here, we have collected evidence of the
effects of MS DMTs, with the aim of identifying those
which offer the greatest benefit in mitigating disability
progression. In addition to summarizing reported trial data
(Tables 1, 2, 3, 4), we have listed for completeness any
ongoing trials of MS DMTs and any trials that have been
withdrawn or stopped (Table 5).
There are difficulties when trying to compare the effi-
cacy of different DMTs in relation to disability outcomes.
Definitions of CDP vary across trials, both in the magni-
tude of the change in EDSS score that constitutes pro-
gression, and in the time over which this change must be
sustained. A 1.5-point change from a baseline EDSS score
of zero is a more robust measure of permanent disease
worsening than a 1.0-point change, because recovery from
a relapse is likely in the early stages of MS. Given that
recovery is also likely if assessments are made over
3 months [18], the European Medicines Agency has rec-
ommended that assessments of disability should be made at
least 6 months apart [17]; however, this recommendation
was made subsequent to the time when the trials reviewed
here were planned.
These challenges notwithstanding, trials of fingolimod,
alemtuzumab, natalizumab laquinimod and subcutaneous
IFN beta-1b in patients with RRMS have demonstrated
significant reductions in the risk of 6-month CDP, effect
sizes being in the range 40–60 % [20, 37, 38, 46, 49, 82]. A
similar effect size is also implied by the proportions of
patients free from 6-month CDP reported for intramuscular
IFN beta-1a [73]. Patient demography at baseline was
broadly similar in the phase III trials that demonstrated
these treatment effects (Table 1), although the period since
symptom onset was shortest in the alemtuzumab trials.
Laquinimod is unusual among this group, in that its impact
on disability was significant but its effect on relapse rates
was modest [37, 38].
Evidence for mitigation of disease worsening in pro-
gressive forms of MS remains sparse, particularly in pa-
tients with PPMS. Treatment effects have been reported for
mitoxantrone in a mixed population of patients with pro-
gressive disease [54], and for subcutaneous IFN beta-1b in
individuals with SPMS [94, 96] but the general lack of
reported values for risk reduction in trials in patients with
progressive MS tends to confound comparisons. Details of
the phase III INFORMS trial of fingolimod in PPMS are
awaited, but it is known that the primary endpoint was not
met [103].
Considerable advances have been made in the last
5 years in the treatment of relapsing MS, but the im-
munomodulatory nature of the majority of DMTs means
that they may have little influence on the pathophysio-
logical mechanisms associated with progressive disease
[104]. Although inflammation is known to occur [105], it
remains unclear whether it precedes or follows neuro-
degenerative tissue injury. However, there is some
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Table 5 Trials of multiple sclerosis (MS) therapies that are active but no longer recruiting, or that have been withdrawn, suspended or
terminated. Trials are only listed if disability endpoints were specified









Curcumin as add-on to subcutaneous IFN
beta-1a
Early active RMS





NCT01047319 Laquinimod RMS BRAVO extension








NCT00803049 Teriflunomide RRMS TEMSO extension
NCT00228163 Teriflunomide RMS Phase II 10-year follow-up
SOLAR
NCT01285401







NCT01433250 AIN457 (secukinumab) RRMS Phase II










NCT01416155 Natalizumab RRMS Phase II Japanese study extension
NCT01412333
NCT01247324
Ocrelizumab ± subcutaneous IFN beta-
1a
RRMS
NCT01194570 Ocrelizumab ? methylprednisolone PPMS
GATEWAY II
NCT01569451





Subcutaneous daclizumab ? IFN beta-1a RRMS Pivotal phase III trial
SELECTED
NCT01051349
Subcutaneous daclizumab RRMS SELECT extension
ATTAIN
NCT01332019
Subcutaneous pegylated IFN beta-1a RRMS Phase III ADVANCE extension
Withdrawn trials—oral therapies
NCT00296205 High-dose cyclophosphamide SPMS
PPMS PRMS
Principal investigator changed institution
NCT00104143 A4i antagonist RMS Withdrawn before enrollment
NCT00429442 Simvastatin as add-on to GA RMS Withdrawn before enrollment
968 H. Wiendl, S. G. Meuth
evidence that targeting inflammatory activity may be
beneficial in certain patients with progressive disease. In
subgroup analyses of the OLYMPUS trial of rituximab in
PPMS [91], there was a significant effect of treatment on
3-month CDP among patients with gadolinium-enhanced
MRI lesions at baseline. This treatment effect was driven
by the fact that disability progression was faster among
patients who received placebo in this subgroup (patients
with disease now classified as ‘active and with progression’
[13]), than among those on placebo who were free from
inflammatory activity at baseline (‘not active but with
progression’ [13]). Age, but not disease duration, also af-
fected outcomes in OLYMPUS: the effect of treatment on
3-month CDP was seen in patients younger than 51 years
of age, but not in older patients [91]. These findings tend to
support the use of the most effective immunomodulatory
therapies early in the disease course among young patients
whose MS is both active and progressive. The lack of effect
Table 5 continued
Trial name Intervention(s) Patient group Comment
Suspended trials—intravenous therapies
NCT00939549 High-dose cyclophosphamide then
subcutaneous GA
RRMS Suspended for revisions to protocol




Teriflunomide RRMS Sponsor decision, not linked to safety
TOFINGO
NCT01499667
Fingolimod RRMS Determination of natalizumab washout
period no longer relevant
RECYCLINE
NCT01134627
Minocycline RRMS No reason recorded
NCT00418145 Oral (vs intravenous) steroids RMS Low enrollment
NCT01516554 Oral testosterone for fatigue RRMS No reason recorded






Memantine All MS types Unexpected, reversible, mild-to-moderate
neurological impairment
Terminated trials—intravenous therapies
NCT00146159 Mitoxantrone SPMS No reason recorded
NCT00219908 Mitoxantrone Early active RRMS No reason recorded
MAESTRO-02
NCT00870155
MBP8298 SPMS Negative efficacy in MAESTRO-01
MAESTRO-03
NCT00468611
MBP8298 SPMS Negative efficacy in MAESTRO-01
STRATA
NCT00297232




ACTH RRMS Study halted after 1 year for data analysis
ATAMS extension
NCT00853762
Atacicept Increased MS disease activity in ATAMS




1a ? subcutaneous GA ? natalizumab
RRMS Terminated by sponsor because of low
enrollment
NCT00784836 Subcutaneous IFN beta-1a (Avonex) RRMS Terminated by sponsor for reasons
unrelated to safety
ACTH adrenocorticotrophic hormone, CIS clinically isolated syndrome, GA glatiramer acetate, IFN interferon, MS multiple sclerosis, PPMS
primary progressive MS, PRMS progressive relapsing MS, RMS relapsing MS, RRMS relapsing–remitting MS, SPMS secondary progressive MS
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among older patients may be symptomatic of age-related
functional changes in immunity, or may be because re-
covery mechanisms are overwhelmed once a certain level
of CNS damage has been accumulated by the combined
effects of disease progression and aging. Either scenario
adds another layer of complexity to the problem of iden-
tifying effective treatments in progressive MS.
Figure 1 illustrates schematically how different factors
might combine in different MS disease types; analogous
schemes have been proposed previously [106, 107]. The
relapsing–remitting disease course is initially driven by
inflammation, characterized by relapses, focal demyeli-
nated lesions and axonal loss in the central nervous system
(CNS), the effects of which are to some degree mitigated
by neuronal plasticity and repair mechanisms [108, 109].
Coinciding with this, diffuse neurodegenerative damage in
normal-appearing white and grey matter (‘underlying pro-
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relapsing–remitting disease
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Disease worsening in patients
with relapsing MS is a
consequence of incomplete
recovery from what is mostly
focal inflammatory disease;
disease progression is
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neurodegenerative damage, a
portion of which is caused by
permanent focal damage. The
colored boxes indicate typical
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EDSS scores, for recruitment
into phase III trials. CIS
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focal disease recedes [105, 109]. In addition to permanent
focal CNS damage, this diffuse neurodegeneration con-
tributes to the long-term brain atrophy characteristic of
disease progression.
Brain atrophy begins early in patients with MS [110], is
one of the best predictors of long-term disability [111,
112] and correlates with worsening disability [113].
Analyses conducted post hoc in a population of patients
with relapsing MS pooled from the three phase III trials of
fingolimod [20–22] revealed a strengthening correlation
between loss of brain volume and increase in EDSS score
over 4 years [113]. During this period, the correlation
between these parameters was also generally stronger in
the group of patients with 6-month CDP than in the
overall analysis population; consistent with these findings,
the average increase in EDSS score over 4 years was
greatest in the quartile of patients with the most brain
volume loss. In the same set of analyses, significant cor-
relations were also seen between brain volume at baseline
and both EDSS score and T2 lesion volume, the former
correlation supporting an association between loss of brain
volume and accrual of disability before enrolment, and the
latter correlation supporting an association between accu-
mulated inflammatory focal CNS damage and brain atro-
phy [113]. These relationships between CNS damage and
disability progression emphasise the need to initiate
treatment to arrest focal inflammatory and diffuse neu-
rodegenerative processes as early as possible. Although
there are both procedural and methodological challenges
in conducting routine monitoring of brain volume in pa-
tients with MS, these challenges should be tackled because
treatment to reduce brain volume loss has been shown to
correlate with beneficial effects on disability [114]. The
effect of different MS DMTs on brain atrophy is reviewed
elsewhere [115].
The evolution of the pathophysiology of MS during the
disease course serves to emphasise the difficulty in com-
paring treatment effects, and confounds long-term ex-
trapolation of effects seen during a 2- or 3-year clinical
trial. Furthermore, changes in EDSS score tend to be
modest over such a period, and long-term follow-up data,
which might corroborate short-term effects on disability,
are currently unavailable for many DMTs; the outcomes of
several ongoing phase III trial extensions will be interest-
ing. Beyond clinical trials, statistical modelling of real-
world data offers a further means to assess the benefits of
different treatments. Although still relatively short-term, a
recent MS registry analysis of 3326 propensity-matched
patients with a median follow-up time of 3.7 years found
no difference among IFN beta therapies and GA in terms of
12-month CDP [116].
Despite great progress in the treatment of patients with
relapsing MS, there remains an urgent need for drugs that
modify the progressive disease course. From the patient’s
perspective, physical and cognitive deterioration is prob-
ably the greatest concern. It is therefore important that
clinical and paraclinical measures that accurately predict
and track disease worsening and progression continue to be
optimized and standardized to inform prescribing
decisions.
5 Conclusions
In relapsing MS, increased numbers of approved DMTs
give clinicians much greater scope than was possible only
5 years ago to select therapy options that their patients
tolerate and which are likely to slow disability progression.
Treatment options for patients with progressive MS remain
scant, but immunomodulatory therapies may be effective in
certain patient phenotypes. Challenges remain in stan-
dardizing how the efficacy of new and existing treatments
is assessed, and assessment of subclinical disease as well as
of relapses and disability progression should become part
of routine disease monitoring. For the best outcomes in
relapsing MS, evidence is accumulating that the most ef-
fective treatments should be used early in the disease
course to reduce inflammatory disease, slow the accumu-
lation of CNS damage and atrophy, and thereby delay the
accrual of disability.
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Glossary of Trials Listed
ACCLAIM A Cooperative Clinical Study of
Abatacept in Multiple Sclerosis




AFFIRM Natalizumab Safety and
Efficacy in Relapsing
Remitting Multiple Sclerosis
ALLEGRO Assessment of Oral Laquinimod
in Preventing Progression in
Multiple Sclerosis
ASCEND A Clinical Study of the Efficacy




ATAMS Atacicept in Multiple Sclerosis,
Phase II
ATTAIN Long-Term Safety and Efficacy
Study of BIIB017 (PEGylated
Interferon Beta-1a)
BENEFIT Betaferon/Betaseron in Newly
Emerging Multiple Sclerosis for
Initial Treatment
BEYOND Betaferon/Betaseron Efficacy
Yielding Outcomes of a New
Dose in Multiple Sclerosis (MS)
Patients
BRAVO Benefit–Risk Assessment of
Avonex and Laquinimod
CARE-MS Comparison of Alemtuzumab
and Rebif Efficacy in Multiple
Sclerosis
CHAMPS Controlled High-Risk Subjects
Avonex Multiple Sclerosis
Prevention Study
CHOLINE A Multicentre Study of the
Efficacy and Safety of
Supplementary Treatment with
Cholecalciferol in Patients with
Relapsing Multiple Sclerosis
Treated with Subcutaneous
Interferon Beta-1a 44 lg
3 Times Weekly
CLARITY Cladribine Tablets Treating
Multiple Sclerosis Orally
CombiRx Combination Therapy in
Patients with Relapsing–
Remitting Multiple Sclerosis
CONFIRM Comparator and an Oral
Fumarate in Relapsing–
Remitting Multiple Sclerosis
CONTAIN Dietary Supplement of Curcumin
inSubjectswithActiveRelapsing
Multiple Sclerosis Treated with
Subcutaneous Interferon Beta 1a
DECIDE Efficacy and Safety of BIIB019
(Daclizumab High Yield
Process) Versus Interferon b 1a
in Participants with Relapsing–
Remitting Multiple Sclerosis
DEFINE Determination of the Efficacy
and Safety of Oral Fumarate in
Relapsing–Remitting Multiple
Sclerosis
EVIDENCE Evidence of Interferon Dose-
Response European North
American Comparative Efficacy
FLORIMS Flupirtine as Oral Treatment in
Multiple Sclerosis
FREEDOMS FTY720 Research Evaluating
Effects of Daily Oral Therapy
in Multiple Sclerosis
GALA Glatiramer Acetate Low-
frequency Administration
GATEWAY II Comparison of Rituximab
Induction Therapy Followed by
Glatiramer Acetate Therapy to
Glatiramer Acetate
Monotherapy for MS
IFNB Interferon Beta-1b Study
IMPACT International MS Secondary
Progressive Avonex Controlled
Trial
IMPROVE Investigating MRI Parameters
with Rebif Improved
Formulation
INCOMIN Independent Comparison of
Interferons
INFORMS Investigating FTY720 Oral in
Primary Progressive MS
MAESTRO A Study for Patients with
Secondary Progressive
Multiple Sclerosis
Memantine-MS Memantine Therapy for
Multiple Sclerosis
MIMS Mitoxantrone in Multiple
Sclerosis Study
MS-SPI Effect of MD1003 in Spinal
Progressive Multiple Sclerosis
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MS-STAT Investigation of Simvastatin in
Secondary Progressive Multiple
Sclerosis
OFAMS x-3 Fatty Acid Treatment in
Multiple Sclerosis
OLYMPUS A Study to Evaluate the Safety
and Efficacy of Rituximab in
Adults with Primary
Progressive Multiple Sclerosis
ORACLE MS Oral cladribine for early MS
PreCISe Early Glatiramer Acetate
Treatment in Delaying
Conversion to Clinically
Definite Multiple Sclerosis in
Subjects Presenting with a
Clinically Isolated Syndrome
PROMiSe Glatiramer Acetate in Primary
Progressive Multiple Sclerosis
PRISMS Prevention of Relapses and
Disability by Interferon Beta-
1a Subcutaneously in Multiple
Sclerosis
RECLAIM Efficacy Study of
Adrenocorticotropin Hormone
to Treat Multiple Sclerosis
(MS) Relapses After Sub-
responding to an Initial 3 Day
Course of Intravenous (IV)
Methylprednisolone
RECYCLINE Minocycline as Add-on to
Interferon Beta-1a [IFN Beta-
1a] (Rebif) in Relapsing–
Remitting Multiple Sclerosis
REFLEX Rebif Flexible dosing in early
MS
REGARD Rebif vs Glatiramer Acetate in
Relapsing MS Disease
SELECTED Safety and Efficacy Extension
Study of Daclizumab High
Yield Process (DAC HYP)





SENTINEL Safety and Efficacy of
Natalizumab in Combination
with Interferon Beta-1a in
Patients with Relapsing–
Remitting Multiple Sclerosis
SOLAR Supplementation of VigantOL
Oil Versus Placebo as Add-on
in Patients with Relapsing
Remitting Multiple Sclerosis
Receiving Rebif Treatment
SPECTRIMS Secondary Progressive Efficacy
Clinical Trial of Recombinant
Interferon-beta-1a in MS
STRATA Natalizumab (Tysabri) Re-
Initiation of Dosing
SUPREMES Sunphenon in Progressive
Forms of Multiple Sclerosis
SURPASS Study Evaluating Rebif,
Copaxone, and Tysabri for
Active Multiple Sclerosis
SWABIMS Swiss Atorvastatin and
Interferon Beta-1b trial In
Multiple Sclerosis
SYNERGY Study to Assess the Efficacy,
Safety, Tolerability, and
Pharmacokinetics of BIIB033
in Participants with Relapsing
Forms of Multiple Sclerosis




TENERE Teriflunomide and Rebif
TERACLES Efficacy and Safety of
Teriflunomide in Patients with
Relapsing Multiple Sclerosis
and Treated with Interferon-
beta
TIME-MS Safety Study of Combination
Therapy with Intramuscular
Avonex and Oral Cellcept in
Patients with Multiple Sclerosis





TOPIC Oral Teriflunomide for Patients
with a First Clinical Episode
Suggestive of Multiple Sclerosis
TOWER Teriflunomide Oral in People
with Relapsing Multiple
Sclerosis
TRANSFORMS Trial Assessing Injectable
Interferon versus FTY720 Oral
in Relapsing–Remitting
Multiple Sclerosis
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